DOP2016000175A - (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 - Google Patents

(2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1

Info

Publication number
DOP2016000175A
DOP2016000175A DO2016000175A DO2016000175A DOP2016000175A DO P2016000175 A DOP2016000175 A DO P2016000175A DO 2016000175 A DO2016000175 A DO 2016000175A DO 2016000175 A DO2016000175 A DO 2016000175A DO P2016000175 A DOP2016000175 A DO P2016000175A
Authority
DO
Dominican Republic
Prior art keywords
feniletil
ciano
oxazepan
carboxamids
inhibitors
Prior art date
Application number
DO2016000175A
Other languages
English (en)
Inventor
Carl-Johan Aurell
Hans Roland LÖNN
Steffan Po Karlsson
John Fritiof Pontén
Stephen Connolly
Steven Swallow
Kelvin James Doyle
Amanda Jane Van De Poël
Graham Peter Jones
David Wyn Watson
Jaqueline Anne Macritchie
Nicholas John Palmer
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52432834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2016000175(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of DOP2016000175A publication Critical patent/DOP2016000175A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

LA PRESENTE DIVULGACIÓN SE REFIERE A DETERMINADOS COMPUESTOS DE (2S)-N-[(1S)-1-CIANO-2-FENILETIL]-1,4-OXAZEPAN-2-CARBOXAMIDA (INCLUIDAS SALES FARMACÉUTICAMENTE ACEPTABLE DE ESTOS), (FÓRMULA (I)) QUE INHIBEN LA ACTIVIDAD DE DIPEPTIDIL PEPTIDASA 1 (DPP1), PARA SU USO EN EL TRATAMIENTO Y/O PREVENCIÓN DE AFECCIONES CLÍNICAS QUE INCLUYEN ENFERMEDADES RESPIRATORIAS, TALES COMO ASMA Y ENFERMEDAD PULMONAR OBSTRUCTIVA CRÓNICA (COPD), A SU USO EN TERAPIA, A COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y A PROCESOS PARA LA PREPARACIÓN DE DICHOS COMPUESTOS.
DO2016000175A 2014-01-24 2016-07-13 (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 DOP2016000175A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461931090P 2014-01-24 2014-01-24

Publications (1)

Publication Number Publication Date
DOP2016000175A true DOP2016000175A (es) 2016-08-15

Family

ID=52432834

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2016000175A DOP2016000175A (es) 2014-01-24 2016-07-13 (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1

Country Status (38)

Country Link
US (19) US9522894B2 (es)
EP (4) EP3323814B1 (es)
JP (8) JP6469711B2 (es)
KR (1) KR102417684B1 (es)
CN (2) CN110483492B (es)
AP (1) AP2016009322A0 (es)
AR (1) AR099177A1 (es)
AU (4) AU2015208932C1 (es)
BR (1) BR112016016224B1 (es)
CA (1) CA2935625C (es)
CL (1) CL2016001889A1 (es)
CR (1) CR20160327A (es)
CY (2) CY1120049T1 (es)
DK (3) DK3744714T3 (es)
DO (1) DOP2016000175A (es)
EA (1) EA032794B1 (es)
ES (3) ES2658516T3 (es)
FI (2) FI3744714T3 (es)
HR (3) HRP20180116T1 (es)
HU (3) HUE052421T2 (es)
IL (3) IL246614B (es)
LT (4) LT3097086T (es)
MX (1) MX368840B (es)
MY (1) MY194850A (es)
NO (2) NO2699580T3 (es)
NZ (2) NZ734768A (es)
PE (1) PE20161218A1 (es)
PH (1) PH12016501439A1 (es)
PL (3) PL3744714T3 (es)
PT (3) PT3323814T (es)
RS (3) RS66709B1 (es)
SG (2) SG11201606052TA (es)
SI (3) SI3097086T1 (es)
SM (3) SMT202000433T1 (es)
TW (1) TWI690517B (es)
UY (1) UY35963A (es)
WO (1) WO2015110826A1 (es)
ZA (2) ZA201605856B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (es) * 2014-01-24 2018-02-24
WO2018022978A1 (en) * 2016-07-29 2018-02-01 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating bronchiectasis
EP3749326A4 (en) * 2018-02-07 2021-11-03 Insmed Incorporated CERTAIN (2S) -N - [(1S) -1-CYANO-2-PHENYLETHYL] -1,4-OXAZEPAN-2-CARBOXAMIDE FOR THE TREATMENT OF VASCULITIDES ASSOCIATED WITH ANCA
FI3758708T3 (fi) * 2018-03-01 2025-02-18 Astrazeneca Ab (2s)-{(1s)-1-syano-2-[4-(3-metyyli-2-okso-2,3-dihydro-1,3-bentsoksatsol-5-yyli)fenyyli]etyyli}-1,4-oksatsepaani-2-karboksamidia käsittäviä farmaseuttisia koostumuksia
KR20210032439A (ko) * 2018-07-17 2021-03-24 인스메드 인코포레이티드 염증성 장 질환을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
KR20210032431A (ko) * 2018-07-17 2021-03-24 인스메드 인코포레이티드 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
CN111689923B (zh) * 2019-03-12 2022-11-08 中国科学院上海药物研究所 一个具有逆转肿瘤多药耐药活性的环脂肽化合物、其制备方法及用途
AU2020370210A1 (en) * 2019-10-23 2022-04-21 Chong Kun Dang Pharmaceutical Corp. Compositions for preventing or treating chronic obstructive pulmonary diseases (COPD)
WO2022013684A1 (en) 2020-07-11 2022-01-20 Pfizer Inc. Antiviral heteroaryl ketone derivatives
CA3181285A1 (en) * 2020-07-20 2022-01-27 Jessica BASSO Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions
RS66302B1 (sr) * 2020-08-26 2025-01-31 Haisco Pharmaceuticals Pte Ltd Derivat nitrila koji deluje kao inhibitor dipeptidil peptidaze 1 i njegova upotreba
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN114159446A (zh) * 2020-09-11 2022-03-11 中国科学院上海营养与健康研究所 组织蛋白酶c抑制剂在治疗肿瘤转移中的应用
CA3199568A1 (en) * 2020-12-04 2022-06-09 Reistone Biopharma Company Limited Small molecule inhibitor of cathepsin c and medicinal use thereof
CN114591315A (zh) * 2020-12-04 2022-06-07 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂
WO2022140516A1 (en) * 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
AU2022218443B2 (en) * 2021-02-05 2025-03-13 Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. Fused ring derivatives containing 1,4-oxazepane
KR20240004691A (ko) * 2021-04-29 2024-01-11 인스메드 인코포레이티드 낭성 섬유증 치료를 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복사미드
CN115925696A (zh) * 2021-10-29 2023-04-07 瑞石生物医药有限公司 一种1-氰基-2-苯基乙基甲酰胺衍生物及其用途
US20250049813A1 (en) * 2021-10-29 2025-02-13 Insmed Incorporated Certain n-(1-cyan0-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
CN116332937B (zh) * 2021-12-23 2026-04-10 杭州邦顺制药股份有限公司 二肽基肽酶ⅰ抑制剂及其用途
US20250101011A1 (en) * 2022-01-11 2025-03-27 Shanghai Yidian Pharmaceutical Technology Development Co., Ltd Peptidyl nitrile compound and use thereof
MX2024009995A (es) * 2022-02-16 2024-08-22 Insmed Inc Determinadas n-(1-ciano-2-feniletil)-1,4-oxazepano-2-carboxamidas para el tratamiento de la hidrosadenitis supurativa.
CN118696040A (zh) 2022-02-22 2024-09-24 西藏海思科制药有限公司 一种二肽基肽酶1抑制剂多晶型物及其制备方法和用途
CA3243683A1 (en) * 2022-02-22 2025-01-22 Haisco Pharmaceuticals Pte. Ltd. SALT AND CRYSTALLINE FORM OF DIPEPTIDYLPEPTIDASE INHIBITOR COMPOUND
EP4484423A4 (en) 2022-02-22 2026-01-07 Haisco Pharmaceuticals Pte Ltd PROCESS FOR PREPARING A HETEROCYCLIC COMPOUND CONTAINING NITROGEN
CN114644562B (zh) * 2022-04-29 2023-08-22 常州大学 具有红移荧光发射的有机小分子荧光化合物、制备方法及应用
JP2025518345A (ja) 2022-06-07 2025-06-12 瑞石生物医薬有限公司 ベンゾ［ｃ］クロマン化合物の薬学的に許容される塩、ならびに薬学的に許容される塩の多形及び使用
TW202404960A (zh) 2022-06-07 2024-02-01 大陸商瑞石生物醫藥有限公司 苯并［ｃ］色滿化合物的多晶型及其製備方法和用途
IL317570A (en) 2022-06-13 2025-02-01 Alivexis Inc Azacycloalkylcarbonyl cyclic amines and their use
WO2024008680A1 (en) 2022-07-06 2024-01-11 Chiesi Farmaceutici S.P.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
EP4602043A1 (en) 2022-10-14 2025-08-20 Genesis Therapeutics, Inc. 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer
WO2024088307A1 (zh) * 2022-10-26 2024-05-02 上海壹迪生物技术有限公司 一种新型肽基腈类化合物及其应用
CN115785083A (zh) * 2022-12-27 2023-03-14 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂及其制备方法
EP4646265A1 (en) 2023-01-06 2025-11-12 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof
WO2024173556A2 (en) * 2023-02-15 2024-08-22 Insmed Incorporated Uses of certain 1,4-oxazepane-2-carboxamides as dpp1 inhibitors
JP2026510407A (ja) 2023-03-23 2026-04-02 ハイスコ ファーマスーティカル プライベート リミテッド ジペプチジルペプチダーゼ小分子阻害剤を含む医薬組成物
AU2024340032A1 (en) * 2023-09-15 2026-04-09 Insmed Incorporated Dipeptidyl peptidase 1 inhibitors and uses thereof
USD1099133S1 (en) * 2024-02-01 2025-10-21 Apple Inc. Display screen or portion thereof showing a graphical user interface
WO2025214073A1 (en) * 2024-04-12 2025-10-16 Insmed Incorporated Dipeptidyl peptidase 1 inhibitors and uses thereof
WO2025250560A1 (en) * 2024-05-28 2025-12-04 Insmed Incorporated Methods for treating bronchiectasis

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2782151B2 (ja) 1993-07-16 1998-07-30 博 吉田 衝撃吸収柵用の端ストッパ
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6462076B2 (en) 2000-06-14 2002-10-08 Hoffmann-La Roche Inc. Beta-amino acid nitrile derivatives as cathepsin K inhibitors
WO2002020804A1 (en) 2000-09-08 2002-03-14 Prozymex A/S Rat cathepsin, dipeptidyl peptidase i (dppi): crystal structure, inhibitors and its uses
ATE407924T1 (de) * 2000-10-06 2008-09-15 Mitsubishi Tanabe Pharma Corp Stickstoffhaltige, fünfgliedrige ringverbindungen
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
KR20050044660A (ko) 2001-12-04 2005-05-12 에프. 호프만-라 로슈 아게 치환된 2-아미노-사이클로알칸카복스아마이드 및 시스테인프로테아제 저해제로서의 이의 용도
US20040253311A1 (en) 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
WO2004076434A1 (en) 2003-02-28 2004-09-10 Aic Dipeptidyl peptidase inhibitors
EP2258365B1 (en) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
US20070155803A1 (en) 2003-05-30 2007-07-05 Prozymex A/S Protease inhibitors
WO2004110988A1 (en) 2003-06-18 2004-12-23 Prozymex A/S Protease inhibitors
AU2005243247B2 (en) 2004-04-07 2012-03-01 Regents Of The University Of Minnesota Methods for treating bone cancer pain by administering a nerve growth factor antagonist
EP2017620A3 (en) 2004-04-28 2009-04-22 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (DPP1)
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
SE0401657D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
EP1916994B1 (en) 2004-06-29 2013-12-11 Takeda Pharma A/S Manufacturing of quick release pharmaceutical composition of water insoluble drugs and pharmaceutical compositions obtained by the process of the invention
WO2006020145A2 (en) 2004-07-19 2006-02-23 The Johns Hopkins University Flt3 inhibitors for immune suppression
WO2006089290A1 (en) 2005-02-18 2006-08-24 Abraxis Bioscience Inc.. Combinations and modes of administration of therapeutic agents and combination therapy
MX2007015679A (es) 2005-06-30 2008-02-21 Amgen Inc Inhibidores de quinasa bis-aril y su uso en el tratamiento de inflamacion, angiogenesis y cancer.
AU2008223348A1 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
WO2009026701A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Sirtuin inhibitors
EP2203155A1 (en) 2007-09-25 2010-07-07 Novartis Ag Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin
KR20100098683A (ko) 2007-12-12 2010-09-08 아스트라제네카 아베 펩티딜 니트릴, 및 디펩티딜 펩티다제 ｉ 억제제로서의 그의 용도
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
UY31867A (es) 2008-06-06 2010-01-29 Boehringer Ingelheim Int Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
CN106336400A (zh) 2008-12-08 2017-01-18 萌蒂制药国际有限公司 酪氨酸激酶蛋白受体拮抗剂
JP5864410B2 (ja) 2009-04-01 2016-02-17 ノヴィファーマ ソシエテ アノニム ニトロカテコール誘導体を含む医薬製剤及びその製造方法
AU2010244218B2 (en) 2009-05-07 2012-07-19 Astrazeneca Ab Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
WO2010142985A1 (en) * 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
RS62767B1 (sr) 2010-04-07 2022-01-31 Vertex Pharma Farmaceutski sastavi 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiriodin-2-il)benzojeve kiseline i njihova primena
WO2011154677A1 (en) * 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
IT1404036B1 (it) 2010-12-17 2013-11-08 Oto Melara Spa Veicolo armato con struttura migliorata.
MX2013009279A (es) 2011-02-11 2013-10-28 Glaxosmithkline Ip Dev Ltd Inhibidores de catepsina c.
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
ES2674451T3 (es) 2012-02-21 2018-06-29 Merck Patent Gmbh 2-amino-[1,2,4]triazolo[1,5-a] pirazinas 8-sustituidos como inhibidores de la SYK tirosina quinasa e inhibidores de la serina quinasa GCN2
CN104284895B (zh) 2012-04-17 2016-08-31 安斯泰来制药株式会社 含氮双环式芳香族杂环化合物
WO2014091443A1 (en) 2012-12-13 2014-06-19 Glaxo Group Limited Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
EP2775304A1 (en) 2013-03-07 2014-09-10 Universitätsspital Basel Methods for detecting inflammatory disorder
WO2014140091A1 (en) 2013-03-14 2014-09-18 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
AU2014230814B2 (en) 2013-03-14 2017-12-21 Boehringer Ingelheim International Gmbh Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C
US8889708B2 (en) 2013-03-14 2014-11-18 Boehringer Ingelheim International Gmbh Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C
JP6441830B2 (ja) 2013-03-14 2018-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（シアノ−メチル）−アミド阻害剤
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CA2907566C (en) 2013-04-01 2023-08-22 Pulmatrix, Inc. Tiotropium dry powders
US10670594B2 (en) 2013-08-22 2020-06-02 Emory University Devices and methods related to airway inflammation
DK3044214T3 (da) 2013-09-09 2017-11-13 Prozymex As Peptidylnitrilforbindelser som dipeptidylpeptidase-I-inhibitorer
WO2015032942A1 (en) 2013-09-09 2015-03-12 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
NO2699580T3 (es) 2014-01-24 2018-02-24
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
EP3831378A1 (en) 2014-04-10 2021-06-09 Novartis AG Siponimod immediate release dosage regimen for treating autoimmune diseases
SMT202000516T1 (it) 2014-05-15 2020-11-10 Insmed Inc Metodi per trattamento di infezioni micobatteriche polmonati non tubercolari
WO2015180687A1 (en) 2014-05-30 2015-12-03 The University Of Hong Kong Methods and compositions for use of neutrophil elastase and proteinase 3 as diagnostic biomarkers
EP3174879B1 (en) 2014-08-01 2018-07-18 Boehringer Ingelheim International GmbH Substituted oxetanes and their use as inhibitors of cathepsin c
UA118610C2 (uk) 2014-09-12 2019-02-11 Бьорінгер Інгельхайм Інтернаціональ Гмбх Спіроциклічні інгібітори катепсину c
CA2965566A1 (en) 2014-11-14 2016-05-19 Boehringer Ingelheim International Gmbh Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (sstr4) agonists
DK3265452T3 (en) 2015-03-05 2020-06-08 Neuprozyme Therapeutics ApS Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
WO2018022978A1 (en) 2016-07-29 2018-02-01 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating bronchiectasis
EP3749326A4 (en) 2018-02-07 2021-11-03 Insmed Incorporated CERTAIN (2S) -N - [(1S) -1-CYANO-2-PHENYLETHYL] -1,4-OXAZEPAN-2-CARBOXAMIDE FOR THE TREATMENT OF VASCULITIDES ASSOCIATED WITH ANCA
FI3758708T3 (fi) 2018-03-01 2025-02-18 Astrazeneca Ab (2s)-{(1s)-1-syano-2-[4-(3-metyyli-2-okso-2,3-dihydro-1,3-bentsoksatsol-5-yyli)fenyyli]etyyli}-1,4-oksatsepaani-2-karboksamidia käsittäviä farmaseuttisia koostumuksia
KR20210032431A (ko) 2018-07-17 2021-03-24 인스메드 인코포레이티드 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
KR20210032439A (ko) 2018-07-17 2021-03-24 인스메드 인코포레이티드 염증성 장 질환을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
KR20230110821A (ko) 2019-04-17 2023-07-25 아조라 테라퓨틱스 인코포레이티드 염증성 피부 질환을 치료하기 위한 국소 조성물 및방법
MX2021014742A (es) 2019-06-05 2022-02-11 Univ Emory Peptidomimeticos para el tratamiento de infecciones por coronavirus y picornavirus.
WO2022140516A1 (en) 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
CN112920124B (zh) 2021-01-29 2024-03-01 安徽医科大学 一种嘧啶-2,4-二胺类化合物及其制备方法与应用
WO2022232420A1 (en) 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer
KR20240004691A (ko) 2021-04-29 2024-01-11 인스메드 인코포레이티드 낭성 섬유증 치료를 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복사미드
US20250049813A1 (en) 2021-10-29 2025-02-13 Insmed Incorporated Certain n-(1-cyan0-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
MX2024009995A (es) 2022-02-16 2024-08-22 Insmed Inc Determinadas n-(1-ciano-2-feniletil)-1,4-oxazepano-2-carboxamidas para el tratamiento de la hidrosadenitis supurativa.

Also Published As

Publication number Publication date
AU2015208932A1 (en) 2016-07-28
EA201691375A1 (ru) 2017-01-30
KR102417684B1 (ko) 2022-07-05
MX368840B (es) 2019-10-18
CL2016001889A1 (es) 2016-12-09
CR20160327A (es) 2016-10-20
SMT202000433T1 (it) 2020-09-10
TW201612167A (en) 2016-04-01
SG10201701056QA (en) 2017-03-30
ES3018635T3 (es) 2025-05-16
CN110483492B (zh) 2023-07-21
ES2658516T3 (es) 2018-03-12
SMT202500137T1 (it) 2025-05-12
US20240132455A1 (en) 2024-04-25
US20230069044A1 (en) 2023-03-02
LTPA2026513I1 (es) 2026-05-11
EP3744714B1 (en) 2025-01-15
RS66709B1 (sr) 2025-05-30
US20180251436A1 (en) 2018-09-06
HRP20180116T1 (hr) 2018-03-23
JP2025072423A (ja) 2025-05-09
US9522894B2 (en) 2016-12-20
PH12016501439B1 (en) 2017-02-06
JP2023156479A (ja) 2023-10-24
US12054465B2 (en) 2024-08-06
US11655221B2 (en) 2023-05-23
US20230062646A1 (en) 2023-03-02
PH12016501439A1 (en) 2017-02-06
MX2016009349A (es) 2016-10-13
ES2808060T3 (es) 2021-02-25
FI3744714T3 (fi) 2025-04-01
AU2017200338A1 (en) 2017-02-02
EP3744714A1 (en) 2020-12-02
JP7714823B2 (ja) 2025-07-29
US20150210655A1 (en) 2015-07-30
CN105980367B (zh) 2019-08-23
AU2015208932B8 (en) 2017-03-09
US11680049B2 (en) 2023-06-20
US11117874B2 (en) 2021-09-14
EP3323814A1 (en) 2018-05-23
JP6804570B2 (ja) 2020-12-23
AU2018202956B2 (en) 2019-05-09
NO2699580T3 (es) 2018-02-24
DK3744714T3 (da) 2025-04-07
PL3097086T3 (pl) 2018-04-30
US11655222B2 (en) 2023-05-23
NZ734768A (en) 2022-09-30
AU2015208932C1 (en) 2017-05-25
SI3744714T1 (sl) 2025-05-30
EP3097086A1 (en) 2016-11-30
LT3744714T (lt) 2025-04-10
HUE052421T2 (hu) 2021-04-28
JP2022096662A (ja) 2022-06-29
WO2015110826A1 (en) 2015-07-30
SMT201800058T1 (it) 2018-03-08
HK1225730B (en) 2017-09-15
KR20160111470A (ko) 2016-09-26
MY194850A (en) 2022-12-19
LT3323814T (lt) 2020-10-26
AU2017200338B2 (en) 2018-03-01
AU2019202675B2 (en) 2020-05-28
PL3744714T3 (pl) 2025-09-08
US20230025351A1 (en) 2023-01-26
SI3323814T1 (sl) 2020-10-30
ZA201800431B (en) 2019-09-25
AU2015208932A8 (en) 2017-03-09
AU2019202675A1 (en) 2019-05-16
US20200017455A1 (en) 2020-01-16
EP3323814B1 (en) 2020-05-13
BR112016016224B1 (pt) 2023-02-23
PE20161218A1 (es) 2016-11-27
SG11201606052TA (en) 2016-08-30
US20230250071A1 (en) 2023-08-10
BR112016016224A2 (es) 2017-08-08
PT3744714T (pt) 2025-04-07
US11655223B2 (en) 2023-05-23
DK3323814T3 (da) 2020-08-03
IL252836A0 (en) 2017-08-31
US11667615B2 (en) 2023-06-06
AR099177A1 (es) 2016-07-06
CN110483492A (zh) 2019-11-22
US20230033573A1 (en) 2023-02-02
CA2935625C (en) 2022-10-18
JP2019070029A (ja) 2019-05-09
US20230278969A1 (en) 2023-09-07
US11814359B2 (en) 2023-11-14
US9815805B2 (en) 2017-11-14
HUE070606T2 (hu) 2025-06-28
US20210238152A1 (en) 2021-08-05
US11655224B2 (en) 2023-05-23
CY1123391T1 (el) 2021-12-31
EP4548972A3 (en) 2025-06-25
JP7157791B2 (ja) 2022-10-20
HK1255870A1 (en) 2019-08-30
JP7336563B2 (ja) 2023-08-31
CY1120049T1 (el) 2018-12-12
JP2017503832A (ja) 2017-02-02
TWI690517B (zh) 2020-04-11
AU2015208932B2 (en) 2017-02-16
US20200247765A1 (en) 2020-08-06
NZ722063A (en) 2017-09-29
JP2025157389A (ja) 2025-10-15
JP2021046423A (ja) 2021-03-25
AU2018202956A1 (en) 2018-05-17
HUE038274T2 (hu) 2018-10-29
IL246614B (en) 2018-02-28
HRP20201147T1 (hr) 2020-12-11
US11673871B2 (en) 2023-06-13
EP3097086B1 (en) 2017-12-13
SI3097086T1 (en) 2018-04-30
US20170057938A1 (en) 2017-03-02
LT3097086T (lt) 2018-02-26
US20230085620A1 (en) 2023-03-23
EP4548972A2 (en) 2025-05-07
PT3097086T (pt) 2018-02-21
US11773069B2 (en) 2023-10-03
NO2026018I1 (no) 2026-04-14
RS56919B1 (sr) 2018-05-31
UY35963A (es) 2015-07-31
PT3323814T (pt) 2020-08-05
US11673872B2 (en) 2023-06-13
US20260055067A1 (en) 2026-02-26
PL3323814T3 (pl) 2020-10-19
JP7628587B2 (ja) 2025-02-10
FIC20265009I1 (fi) 2026-04-18
US20230116721A1 (en) 2023-04-13
US10287258B2 (en) 2019-05-14
EA032794B1 (ru) 2019-07-31
US20230028726A1 (en) 2023-01-26
ZA201605856B (en) 2020-02-26
US10669245B2 (en) 2020-06-02
CN105980367A (zh) 2016-09-28
US20240336582A1 (en) 2024-10-10
HRP20250302T1 (hr) 2025-04-25
RS60639B1 (sr) 2020-09-30
CA2935625A1 (en) 2015-07-30
US20230115170A1 (en) 2023-04-13
IL265611A (en) 2019-05-30
JP2026065113A (ja) 2026-04-14
AP2016009322A0 (en) 2016-07-31
DK3097086T3 (en) 2018-02-05
JP6469711B2 (ja) 2019-02-13

Similar Documents

Publication Publication Date Title
CR20160327A (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
MX2018010894A (es) Nuevos inhibidores de fosfatidilinositol 3-quinasa gamma.
DOP2014000059A (es) Derivados de estra–1,3,5(10),16–tetraen–3–carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
ECSP19027780A (es) Derivados de 5-[2-(piridin-2-ilamino)-1,3-tiazol-5-il]-2,3-dihidro-1h-isoindol-1-ona y su uso como inhibidores dobles de fosfatidilinositol 3-cinasa delta y gamma
BR112012023660B8 (pt) usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
UY33191A (es) Derivados de pirazina
CL2013002129A1 (es) Compuestos derivados de acido 3-heteroaroilamino-propionico sustituidos, como inhibidores de la proteasa catepsina a; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso para el tratamiento de insuficiencia cardiaca, enfermedades inmunologicas, asma, dolor, entre otras.
MX2017012272A (es) Solucion para inhalacion de tiotropio para nebulizacion.
CR20130693A (es) Composición farmacéutica ortalmológica tópica que contiene regorafenib
UY33723A (es) ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?.
MX2015003732A (es) Tratamiento de enfermedad de alzheimer leve y moderada.
CL2013002325A1 (es) Compuestos derivados de 4-amino-2-butenamidas, inhibidores de catepsina c; composicion farmaceutica que los comprende; procedimiento de preparacion de la composicion farmaceutica; uso del compuesto en el tratamiento de enfermedad pulmonar obstructiva cronica.
MX2019001701A (es) Composicion farmaceutica de dosis fija que comprende mometasona y azelastina.
TH181788A (th) (2s)-n-[(1s)-1-ไซยาโน-2-ฟีนิลเอทิล]-1,4-อ๊อกซาซีเพน-2-คาร์โบซาไมด์ ที่แน่นอนเป็นตัวยับยั้งไดเพปทิดิลเพปทิเดส 1
MX2018010008A (es) Derivado de piperidina y sus métodos de uso.
AR105921A1 (es) Compuestos terapéuticos para el dolor y síntesis de estos